Literature DB >> 21796541

Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease.

Ignacio Obeso1, Leonora Wilkinson, Marjan Jahanshahi.   

Abstract

Evidence from animal, clinical, and imaging studies suggests that the basal ganglia and their frontal connections mediate motor inhibition, but the role of dopamine remains unclear. The aim of our study was to investigate, for the first time, whether levodopa medication influences motor inhibition and conflict resolution on the conditional stop-signal reaction time task in patients with Parkinson's disease (PD) tested on or off their medication. Sixteen PD patients and 17 healthy controls performed the conditional stop-signal reaction time (SSRT) task, which requires inhibition of responses when a stop signal is presented on "critical" trials. Additionally, on "non-critical" trials, participants are instructed to ignore the stop signal and respond, thus generating conflict between motor inhibition and initiation; and conflict-induced slowing (CIS) on these "non-critical" trials. Levodopa medication did not significantly influence response initiation, inhibition (SSRT) or the measure of conflict resolution (CIS). Compared to healthy controls, PD patients showed significantly worse response initiation and inhibition both on and off their levodopa medication. Our results suggest that motor inhibition or conflict-induced slowing on the conditional stop-signal RT task are not altered by dopamine replacement in PD. This conclusion is consistent with evidence from animal studies and clinical pharmacological investigations suggesting a role for noradrenaline in motor inhibition and impulsivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796541     DOI: 10.1007/s00221-011-2793-x

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  56 in total

Review 1.  Opponency revisited: competition and cooperation between dopamine and serotonin.

Authors:  Y-Lan Boureau; Peter Dayan
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

2.  Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status.

Authors:  S L Pullman; R L Watts; J L Juncos; J N Sanes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder.

Authors:  Adam R Aron; Jonathon H Dowson; Barbara J Sahakian; Trevor W Robbins
Journal:  Biol Psychiatry       Date:  2003-12-15       Impact factor: 13.382

Review 5.  Dopamine dysfunction in borderline personality disorder: a hypothesis.

Authors:  Robert O Friedel
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

Review 6.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  Andrew H Evans; Antonio P Strafella; Daniel Weintraub; Mark Stacy
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

7.  Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder.

Authors:  C C E Overtoom; M N Verbaten; C Kemner; J L Kenemans; H van Engeland; J K Buitelaar; M W van der Molen; J van der Gugten; H Westenberg; R A A Maes; H S Koelega
Journal:  Behav Brain Res       Date:  2003-10-17       Impact factor: 3.332

8.  Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination.

Authors:  A A Harrison; B J Everitt; T W Robbins
Journal:  Behav Brain Res       Date:  1999-04       Impact factor: 3.332

9.  Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal and orbitofrontal cortex during a test of impulsive choice.

Authors:  Catharine A Winstanley; David E H Theobald; Jeffrey W Dalley; Rudolf N Cardinal; Trevor W Robbins
Journal:  Cereb Cortex       Date:  2005-04-13       Impact factor: 5.357

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  28 in total

1.  Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.

Authors:  Daniel O Claassen; Wery P M van den Wildenberg; Madaline B Harrison; Nelleke C van Wouwe; Kristen Kanoff; Joseph S Neimat; Scott A Wylie
Journal:  Pharmacol Biochem Behav       Date:  2014-11-29       Impact factor: 3.533

Review 2.  On the Globality of Motor Suppression: Unexpected Events and Their Influence on Behavior and Cognition.

Authors:  Jan R Wessel; Adam R Aron
Journal:  Neuron       Date:  2017-01-18       Impact factor: 17.173

Review 3.  Trends and issues in characterizing early cognitive changes in Parkinson's disease.

Authors:  Daniel O Claassen; Scott A Wylie
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 4.  Impulsivity and apathy in Parkinson's disease.

Authors:  Nihal Sinha; Sanjay Manohar; Masud Husain
Journal:  J Neuropsychol       Date:  2013-04-29       Impact factor: 2.864

5.  Compensatory stepping in Parkinson's disease is still a problem after deep brain stimulation randomized to STN or GPi.

Authors:  R J St George; P Carlson-Kuhta; L A King; K J Burchiel; F B Horak
Journal:  J Neurophysiol       Date:  2015-06-24       Impact factor: 2.714

6.  Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.

Authors:  Silvia Picazio; Viviana Ponzo; Carlo Caltagirone; Livia Brusa; Giacomo Koch
Journal:  J Neurol       Date:  2018-07-06       Impact factor: 4.849

7.  Prefrontal-Subthalamic Hyperdirect Pathway Modulates Movement Inhibition in Humans.

Authors:  Witney Chen; Coralie de Hemptinne; Andrew M Miller; Michael Leibbrand; Simon J Little; Daniel A Lim; Paul S Larson; Philip A Starr
Journal:  Neuron       Date:  2020-03-09       Impact factor: 17.173

8.  Movement activation and inhibition in Parkinson's disease: a functional imaging study.

Authors:  Elizabeth A Disbrow; Karen A Sigvardt; Elizabeth A Franz; Robert S Turner; Kim A Russo; Leighton B Hinkley; Timothy J Herron; Maria I Ventura; Lin Zhang; Norika Malhado-Chang
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

9.  Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's disease.

Authors:  Emilie Favre; Bénédicte Ballanger; Stéphane Thobois; Emmanuel Broussolle; Philippe Boulinguez
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

10.  Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's disease.

Authors:  Ignacio Obeso; Leonora Wilkinson; Maria-Cruz Rodríguez-Oroz; Jose A Obeso; Marjan Jahanshahi
Journal:  Exp Brain Res       Date:  2013-03-23       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.